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Background: Although rituximab in the combination of CHOP chemotherapy has been widely used as the
standard treatment for several kinds of B-cell non-Hodgkin lymphoma (B-NHL), a great number of B-NHL patients
treated with this immunotherapy still develop primary and secondary resistance. Recently Bruton’s tyrosine kinase
(Btk) inhibitor ibrutinib showed promising therapeutic effect in relapsed/refractory CLL and B-cell NHL, which
provided essential alternatives for these patients.
Methods: The proliferation and apoptosis induction of tumor cells were measured by cell viability assay and
Annexin-V staining. Western Blotting analysis and real-time PCR were used to detect the expression level of target
proteins and chemokines production.
Results: We demonstrated that ibrutinib inhibited the proliferation and induced apoptosis of GCB-DLBCL cell lines
through suppression of BCR signaling pathway and activation of caspase-3. Furthermore, the chemokines CCL3 and
CCL4 production from tumor cells were also found to be attenuated by ibrutinib treatment. But different cell lines
exhibited distinct sensitivity after ibrutinib treatment. Interestingly, the decreasing level of p-ERK after ibrutinib
treatment, but not the basal expression level of Btk, correlated with different drug sensitivity.
Conclusions: Ibrutinib could be a potentially useful therapy for GCB-DLBCL and the decreasing level of p-ERK could
become a useful biomarker to predict related therapeutic response.
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Diffuse large B cell lymphoma (DLBCL), the most com-
mon subtype of non-Hodgkin lymphoma (NHL) with ag-
gressive property could be divided into three subgroups
based on gene expression profile: germinal centre B cell-
like DLBCL (GCB-DLBCL), activated B cell-like DLBCL
(ABC-DLBCL) and primary mediastinal B cell lymphoma
[1,2]. R-CHOP, a combination of rituximab plus chemo-
therapy including cyclophosphamide, doxorubicin, vincris-
tine and prednisolone, has been established as the first-line
treatment for DLBCL, but approximately 30–40% of pa-
tients still become primary and secondary resistant to these
drugs [3,4]. So there is an urgent demand for the novel* Correspondence: zhu-jun@bjcancer.org
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unless otherwise stated.target therapy, which could provide alternatives for the
treatment of individuals with recurrent or refractory
disease.
B cell antigen receptor (BCR) signaling pathway has
been recognized essential for the development of normal
B cell and pathogenesis of B cell malignancies [5-8].
Bruton tyrosine kinase (Btk), a crucial regulator within
the BCR signaling pathway, belongs to non-receptor
tyrosine kinase of Tec family that expressed in many
hematopoietic lineages [9]. After antigen binding
to BCR complex, Btk translocates from cytoplasm to
membrane, clocking at IPI3 converted from IPI2 by
PI3K [10,11]. After the phosphorylation at Tyr551 and
Tyr223 residues, Btk activates phospholipase C gamma
2 (PLCγ2), which leads to Ca2+ mobilization and PKC
activation [12,13]. PKC propagates downstream path-
ways such as nuclear factor κB (NF-κB) signaling andLtd. This is an Open Access article distributed under the terms of the Creative
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that regulates cellular survival and apoptotic responses
[14-17]. Thus, targeting small molecules within BCR sig-
naling pathway, especially Btk inhibition would be a novel
approach for treating B cell lymphomas.
In recent years, several novel agents targeting BCR sig-
naling pathway, especially ibrutinib (PCI-32765), have
shown great anti-lymphoma activities in preclinical
study and clinical trials [18-20]. Ibrutinib is an irrevers-
ible and selective Btk inhibitor, which binds covalently
to the target cysteine-481 residue [21]. In preclinical re-
search, ibrutinib showed its cytotoxicity towards B cell
malignancies, including chronic lymphocytic leukemia
(CLL) and mantle cell lymphoma (MCL) by preventing
Btk auto-phosphorylation [22,23]. Furthermore, 60% of
patients with relapsed or refractory B cell malignancies
achieved an objective response in a phase I open-label
clinical trial [24].
The constitutive activation of NF-κB signaling sustained
by chronic BCR pathway plays an essential role in prolifer-
ation of ABC-DLBCL cells, which had been demonstrated
through shRNA interference experiment [25-27]. Al-
though it is reported that the survival of GCB-DLBCL
did not so much rely on activated NF-κB pathway [27],
in our investigation we indeed found that the viability of
some GCB-DLBCL cell lines was also inhibited by ibru-
tinib and different GCB-DLBCL cell lines showed di-
verse sensitivity.
Results
Ibrutinib inhibited the proliferation of GCB-DLBCL cell
lines in a dose- and time-dependent manner
Firstly, we investigated the anti-tumor effects of ibrutinib
in GCB-DLBCL cell lines SU-DHL-16 and OCI-Ly7.
The cell viability assay demonstrated that the prolifera-
tion of tumor cells was inhibited by ibrutinib in a dose
and time dependent manner (Figure 1A and B). But
these two cell lines exhibited different drug sensitivity
toward ibrutinib treatment. The IC50 values were 2.027
and 8.293 μM in SU-DHL-16 cells and OCI-Ly7 cells,
respectively.
Ibrutinib induced cell apoptosis in GCB-DLBCL cell lines
by caspase dependent pathway
To further investigate the mechanisms involved in
anti-proliferation process by ibrutinib, Annexin-V and
PI staining apoptotic cells were analyzed by flow cytome-
try. According to the previous results from cell viability
assay and the dose of ibrutinib wildly used in inhibition of
tumor growth in primary CLL cells [22], the concentration
of 10 μM was used for subsequent experiments to demon-
strate its anti-tumor activities in vitro. As shown in
Figure 2A, SU-DHL-16 cells were tracked from Annexin-
V and PI negative (no apoptosis) to Annexin-V positiveand PI negative (early stage apoptosis) and finally to
Annexin-V and PI dual positive (late stage apoptosis). The
percentages of apoptotic cells in early and late stage were
both gradually increased from 6 to 72 hours after ibrutinib
incubation, which suggested that apoptosis induced by
ibrutinib was time-dependent. But the apoptosis of OCI-
Ly7 cells was not obviously induced by ibrutinib treatment
(Figure 2B). It is reported that activation of caspase-3 and
PARP is associated with the induction of apoptosis, there-
fore we detected the level of caspase-3 and PARP protein
by Western Blot. As shown in Figure 2C, the caspase 3
and PARP cleavage were detected in both cell lines, which
suggested an involvement of caspase pathway in ibrutinib
induced apoptosis. But the density of caspase 3 and PARP
cleavage in SU-DHL-16 cells was much higher than that
in OCI-Ly7 cells, which confirmed the results from flow
cytometry. This result also indicated that SU-DHL-16 cells
were more sensitive to ibrutinib treatment than OCI-Ly7
cells.
Ibrutinib down-regulated CCL3 and CCL4 gene expression
in GCB-DLBCL cell lines
It is reported that chemokines CCL3 and CCL4 secreted
by B-CLL cells were highly regulated by BCR signaling
pathway [28,29]. After the ibrutinib treatment, the mRNA
expression of CCL3 and CCL4 from GCB-DLBCL cells
were detected by Real-Time PCR. As shown in Figure 3,
ibrutinib decreased the level of CCL3 and CCL4 gene ex-
pression in both cell lines, but the decreasing degree in
SU-DHL-16 were much lower than that in OCI-Ly7 after
ibrutinib treatment (p < 0.05).
The basal level of Btk expression was not associated with
different sensitivity to ibrutinib in GCB-DLBCL cell lines
Since ibrutinib exhibited distinct inhibitory activities in
different GCB-DLBCL cell lines, next we sought to inves-
tigate the key regulator determined the response efficacy
to Btk inhibition. Firstly, the expression of Btk in cells was
examined at both mRNA and protein level. Compared
with Jurkat cell line, three DLBCL cell lines had high level
of Btk mRNA expression and the expression difference
between GCB-DLBCL cell lines SU-DHL-16 and OCI-Ly7
was not statistically significant (Figure 4A). Phospho-Btk
proteins were also observed at similar elevated levels in all
three DLBCL cell lines (Figure 4B). The results revealed
that the basal level and phosphorylation status of Btk
expression were not associated with different sensitivity
towards ibrutinib.
Phosphorylation of ERK predicted the different response
to ibrutinib
Next we examined whether the different sensitivities be-
tween GCB-DLBCL cell lines attributed to the different
inhibitory activities of activated BCR signal by ibrutinib.
Figure 1 Ibrutinib inhibited the proliferation of GCB-DLBCL cell lines in a dose- and time-dependent manner. (A) SU-DHL-16 and
OCI-LY7 cells (1 × 105/ml) were treated with the increasing concentrations (0.02 to 25 μM) of ibrutinib or DMSO for 24 hours. (B) SU-DHL-16 and
OCI-LY7 cells (1 × 105/ml) were treated with10 μM of ibrutinib or DMSO for 6 to 48 hours. The viability of cells was determined using the Cell
Titer-Glo luminescent cell viability assay as described in Materials and Methods. Results were expressed as the mean ± SD from triplicate cultures.
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was similarly inhibited by ibrutinib in both sensitive cell
line SU-DHL-16 and not-sensitive cell line OCI-Ly7,
which suggested that ibrutinib induced the anti-lymphoma
effect on GCB-DLBCL cell lines through the inhibition
of BCR signal pathway. But phosphorylation of ERK was
obviously inhibited by ibrutinib in SU-DHL-16 cells other
than in OCI-Ly7 cells. These data demonstrated that inhib-
ition of p-ERK, but not p-Btk and p-PLCγ2 determined the
different sensitivity towards ibrutinib treatment.
Discussion
In this experiment we investigated the inhibition effects
induced by ibrutinib in GCB-DLBCL cells. Tumor cell
proliferation was inhibited by ibrutinib in a dose- and
time-dependent manner in both cell lines, but the IC50
value of OCI-LY7 cells was 4.4 times higher than that ofSU-DHL-16 cells. SU-DHL-16 cells were more sensitive
towards ibrutinib treatment than OCI-Ly7 cells.
Many investigations have shown that the targeted inhib-
itors of crucial tyrosine kinases in BCR signaling pathway,
such as Syk inhibitor PRT060318 and the inhibitor of
Src family kinases (SFKs) dasatinib, could prevent the
proliferation of GCB-DLBCL cell lines by causing cell-
cycle arrest or inducing cell apoptosis [30,31]. Our results
above also demonstrated that ibrutinib, as an important
inhibitor of BCR signal activation and transduction,
inhibited proliferation of tumor cells in a dose and time
dependent manner.
Herman et al. has demonstrated that ibrutinib could in-
duce apoptosis in CLL cells through caspase-dependent
pathway [22]. Similarly, we also found that ibrutinib could
induce a time-dependent apoptosis with the degradation
of caspase-3 and cleavage of PARP in SU-DHL-16 but not
Figure 2 Ibrutinib induced cell apoptosis in GCB-DLBCL cell lines by caspase dependent pathway. (A and B) SU-DHL-16 and LY7 cells
(1 × 105/ml) were treated with a concentration of 10 μM of ibrutinib for 6–72 hours and Annexin-V and PI staining apoptotic cells were analyzed
by flow cytometry. Cells in early stage apoptosis were defined as Annexin-V positive and PI negative and cells in late stage apoptosis were
defined as Annexin-V and PI dual positive. (C) SU-DHL-16 and OCI-LY7 cells (1 × 105/ml) were treated with10 μM of ibrutinib or DMSO for 24 hours.
Then the total protein was prepared and the caspase 3 degradation and PARP cleavage were detected by Western Blot. β-actin was blotted as a
loading control. Results were shown from one of three experiments and the representative results were shown in the figures.
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sensitivity towards ibrutinib treatment between different
GCB-DLBCL cell lines.
It is reported that the secretory chemokines CCL3 and
CCL4 played an important role in the cross talk between
CLL cells and their microenvironment, which promoted
the proliferation and metastasis of tumor cells [28,29].
Ponader et al. demonstrated that ibrutinib down-regulated
the secretion of chemokines CCL3 and CCL4 in CLL cells
both in vitro and in vivo [32]. In our experiment, we
also observed that the expression of CCL3 and CCL4
were dramatically decreased after treatment of ibrutinib,
but the decreasing degree were much more obviously
observed in SU-DHL-16 than that in OCI-Ly7 (p < 0.05).
Many reported demonstrated that the activation sta-
tus of downstream kinases related to outcome of the
target inhibitor. Yang et al. found that dasatinib inducedconsiderable reduction in the phosphorylation of Syk
and PLCγ2 in sensitive cell lines, other than in resist-
ance cell lines [30]. Phosphorylated-Syk and PLCγ2
might serve as potential biomarkers to predict response
to dasatinib treatment. In much the same way, Cheng
et al. also found that phosphorylation of PLCγ2 and
AKT was reduced in a dose-dependent fashion in sensi-
tive but not resistant cell lines after Syk inhibitor
PRT060318 treatment [31]. Thus, to further investigate
the possible mechanisms of different sensitivities to-
wards ibrutinib treatment, the basal level and phosphor-
ylation status of key regulatory enzymes (Btk, PLCγ2
and Erk1/2) of BCR signal pathway were analyzed by
western blotting. We examined the phosphorylation of
Btk and downstream molecular PLCγ2 and ERK in
GCB-DLBCL cells lines before and after ibrutinib treat-
ment. Phosphorylation of Btk and PLCγ2 was similarly
Figure 3 Ibrutinib down-regulated CCL3 and CCL4 gene expression in GCB-DLBCL cell lines. SU-DHL-16 and LY7 cells (1 × 105/ml) were
treated with a concentration of 10 μM of ibrutinib for 12 hours. Then total RNA was extracted by TRIzol reagent and performed a reverse transcription.
RealTime-PCR analysis was done to determine the quantities of CCL3 and CCL4 mRNA. β-actin was used as the internal control gene for normalization.
The expression levels of CCL3 and CCL4 of SU-DHL-16 cells after ibrutinib treatment were shown in Figure 3A and Figure 3B. The expression levels of
CCL3 and CCL4 of OCI-Ly7 cells after ibrutinib treatment were shown in Figure 3C and Figure 3D. Results were expressed as the mean ± SD of
three independent experiments. The differences in groups were assessed by Student’s t-test (p < 0.05).
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ation of ERK was dramatically inhibited in SU-DHL-16
cells but not in OCI-Ly7 cells. Therefore, inhibitory
level of p-ERK could be an important response pre-
dictor to ibrutinib. On the other hand, the distinct gen-
etic background of SU-DHL-16 and OCI-LY7 cells may
also contribute to the different sensitivity toward ibruti-
nib treatment, but the further experiments are needed
to investigate the possible mechanisms in detail.
Together, in this study we revealed that ibrutinib inhib-
ited the proliferation of GCB-DLBCL cell lines through
down-regulation of BCR signaling pathway and activation
of caspase-3. Phosphorylation level of ERK in GCB-DLBCL
could be a useful response predictor to ibrutinib.
Materials and methods
Reagents and antibodies
Ibrutinib was purchased from Selleck Chemicals (Hous-
ton, TX, USA. Cat No. S2680) and dissolved to a 40 mM
stock solution in dimethylsulfoxide (DMSO). Antibodies
for phospho-Tyr223-Btk (5082), phospho-ERK1/2 (4370),
phospho-Tyr759-PLCγ2 (3874), Btk (8547), ERK1/2 (9102),PLCγ2 (3872) and Caspase-3 (9662) used in western
blotting were all purchased from Cell Signaling Technol-
ogy (Danvers, MA, USA). Anti-PARP antibody was
obtained from BD Pharmigen (Cat No.556362, BD
Pharmigen, San Jose, California, USA). β-actin used as
an internal control for western blotting was generated
by Sigma-Aldrich (Cat No. A5441, Sigma-Aldrich, St.
Louis, MO, USA). HRP-conjugated anti-rabbit IgG
(Cat No.458) and HRP-conjugated anti-mouse IgG
(Cat No.330) were purchased from MBL (MBL International
Corporation, Nagoya, Aichi-ken, Japan).Cell lines and culture conditions
The non-Hodgkin lymphoma cell lines SU-DHL-16, OCI-
Ly3 and OCI-Ly7 were obtained from Professor Fu Kai in
University of Nebraska Medical Center. The SU-DHL-16
and OCI-Ly7 cell lines possess t(14;18)(q32;q21) and t
(8;14)(q24;q32) translocation, respectively. These cell lines
were cultured in Dulbecco’s modified Eagle’s medium
(DMEM; Invitrogen, Life Technologies, Carlsbad, CA,
USA) supplemented with 10% fetal bovine serum (FBS;
Figure 4 The basal level of Btk expression was not associated with different sensitivity to ibrutinib in GCB-DLBCL cell lines. (A)
Total RNA from untreated Jurkat, OCI-Ly3, SU-DHL-16, LY7 and normal B cells were extracted by TRIzol reagent and performed a reverse
transcription. RealTime-PCR analysis was done to determine the quantities of Btk mRNA. β-actin was used as the internal control gene for
normalization. Results were expressed as the mean ± SD of three independent experiments. The differences in groups were assessed by Student’s t-test
(p < 0.05). (B) Untreated Jurkat, OCI-Ly3, SU-DHL-16, LY7 and normal B cells were lysed using RIPA buffer for total protein. Western Blot was performed
to detect the expression of p-Btk and Btk protein. β-actin was included as a loading control. Results were shown from one of three experiments and
the representative results were shown in the figures.
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streptomycin in humidified 5% CO2 at 37°C.
Cell viability assay
In vitro cytotoxicity assays were performed by Cell
Titer-Glo Luminescent Cell Viability Assay (Cat No.
G7572, Promega Corporation, Madison, WI, USA). Cell
lines were plated in opaque-walled 96-well plates at a
density of 1 × 105/ml and incubated with various con-
centrations of ibrutinib for 24 hours. Then, 20 μL of
the assay reagent was added to each well, and the cell
lysates were incubated on an orbital shaker at room
temperature for 10 minutes. Luminescent signal was
measured by LMax II (Molecular Devices, Sunnyvale,
CA, USA). The half maximal inhibitory concentration (IC50) of ibrutinib was calculated using Graphpad prism 5
software (GraphPad Software Inc., San Diego, CA, USA).
Western blotting
Cell lines treated or non-treated with ibrutinib were
harvested and lysed using RIPA buffer (Cat No. 9806,
Cell Signaling Technology, Danvers, MA, USA) supple-
mented with protease inhibitor cocktail tablets (Cat No.
04693124001, Roche, Mannheim, Baden-Wuerttemberg,
Germany) to get the protein in total cell extracts. Then
equivalent amounts of protein were separated by sodium
dodecyl sulfate polyacrylamide gel electrophoresis (SDS-
PAGE) on which separating gel contained 4-15% acryl-
amide (Cat No. 456–1083, Bio-Rad, Hercules, CA, USA),
transferred to polyvinylidene fluoride (PVDF) membrane
Figure 5 Phosphorylation of ERK predicted the different response to ibrutinib. Cells (1 × 105/ml) were incubate with ibrutinib at a
concentration of 10 μM for 24 hours, then lysed using RIPA buffer for the total protein. The expression of p-Btk, p-PLCγ2, p-ERK and Btk, PLCγ2,
ERK protein was detected by Western Blot. β-actin was included as a loading control. Results were shown from one of three experiments and the
representative results were shown in the figures.
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MA, USA) and probed with appropriate primary and sec-
ondary antibodies mentioned above to study the BCR sig-
naling pathway and apoptosis-related protein. ECL
select western blotting detection reagent (Cat No. RPN
2235, GE Healthcare, Little Chalfront, Bukinghamshire,
UK) was used for detection on a Fluor Chem HD2
(Cell Biosciences, Santa Clara, CA, USA).
Quantification of apoptosis
After incubated with ibrutinib or not for the indicated
periods, 1 × 106 cells were washed with cold PBS, labeled
using Annexin-V-FITC and propidiumiodide (PI) in bind-
ing buffer according to the manufacturer’s protocol of the
Annexin-V-FITC apoptosis detection kit purchased from
Beijing Biosea Biotechnology (Cat No. CX1001, Beijing,
China) and analyzed by BD Accuri C6 flow cytometer (BD
Biosciences, San Jose, California, USA). Early stage apop-
tosis cells were defined as Annexin-V positive and PI
negative and late stage apoptosis cells were defined as
Annexin-V and PI dual positive.
RNA extraction and real-time PCR
Total RNA was extracted using TRIzol reagent (Cat No.
15596–026, Life Technologies, Carlsbad, CA, USA), ac-
cording to the manufacturer’s instructions. Reverse tran-
scription was performed using TransScript First-Strand
cDNA Synthesis SuperMix (Cat No. AT301, TransGen
Biotech, Beijing, China). Real-Time PCR was performedwith the specially designed primers and probes and Plat-
inum Quantitative PCR SuerMix-UDG (Cat No.11730-
017, Life Technologies, Carlsbad, CA, USA). The primers
and probes were as follows: Btk sense CCGGAAGA-
CAAAAAAGCCTCTT, antisense GGCGGTAGTGGCTT
TTTCAA, Probe FAM-CCCAACGCCTGAGGAGGACC
AGA-TAMRA; CCL3 sense GAGCCCACATTCCGTCA
CCT, antisense CACTGGCTGCTCGTCTCAAA, Probe
FAM-CCACTGCTGCCCTTGCTGTCC-TAMRA; CCL4
sense CAGCGCTCTCAGCACCAA, antisense AGCTT
CCTCGCAGTGTAAGAAAA, Probe FAM-CTCAGACC
CTCCCACCGCCTGC-TAMRA; ACTB sense CCTGGC
ACCCAGCACAAT, antisense GCCGATCCACACGGAG
TACT, Probe FAM-ATCAAGATCATTGCTCCTCCTGA
GCGC-TAMRA. After UDG incubation (50°C for 2 min)
and pre-amplification (95°C for 2 min), the PCR was amp-
lified for 40 cycles (95°C for 15 s and 60°C for 30 s) on a
ABI 7500 Real Time PCR System (Life Technologies,
Carlsbad, CA, USA). The fold change in mRNA was cal-
culated by the 2-ΔΔCt method.Preparation of human peripheral blood B cells
Peripheral blood lymphocytes were isolated from 15 ml
EDTA-blood obtained from healthy volunteers using
Lymphocyte Separation Medium (Cat No. LTS1077, Tian
Jin Hao Yang Biological Manufacture CO.,LTD, Tianjin,
China) according to the protocol from the manufac-
turer. Normal B cells were separated from the peripheral
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human (Cat No. 130-093-660, Miltenyi Biotec, Bergisch
Gladbach, Germany) according to the protocol from the
manufacturer. This research protocol was approved by
our Institutional Review Board.
Statistical analysis
Statistical significance from controls was assessed by
Student’s t-test and p < 0.05 values were accepted as statis-
tically significant. Results represent the mean ± standard
deviation (SD) of three independent experiments. Western
blotting experiments were repeated three times or more
and the representative results were shown in the figures.
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